Clinical trials: Movement Abnormalities
Parkinson´s Disease
Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
Evaluate the benefits of Kinesia-360™ wearable technology in addition to standard clinical practice on improving Parkinson´s disease motor symptoms, Neupro dosing regimen and adherence to Neupro compared with only standard…
- Trial name
- NCT03103919
- Testing
- Kinesia-ONE™, Kinesia-360™, Rotigotine
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma S.P.R.L.
Parkinson's Disease
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
- Trial name
- NCT00292227
- Testing
- Rotigotine, Moxifloxacin infusion
- Where
- 2 sites in South Africa
- Volunteers
- 130 people
- Sponsor
- UCB Pharma
Depression, Parkinson's Disease
Telehealth Cognitive Behavioral Therapy for Depression in Parkinson's Disease (PD)
When Veterans with Parkinson's disease (PD) suffer from depression, they are more likely to experience disease complications, interpersonal difficulties with caregivers, and poorer quality of life.
- Trial name
- TH-CBT (NCT02475954)
- Testing
- TH-CBT, Standard Care
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Utilization of Target Ranges to Treat Parkinson's Disease With the PKG
The main objective of this study is to evaluate whether people whose PD symptoms are uncontrolled who are managed with the aid of objective measurement and use of target ranges have improved PD symptoms and outcomes as compared…
- Trial name
- TARGET-PD (NCT03984305)
- Testing
- Personal KinetiGraph® (PKG®) Watch, Personal KinetiGraph® (PKG®) Report
- Where
- 17 sites in United States
- Volunteers
- 41 people
- Sponsor
- Global Kinetics Corporation
Bowel Incontinence
A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage
The purpose of this study is to determine whether the use of the Renew Insert is effective, tolerable and safe in the treatment of accidental bowel leakage due to bowel incontinence.
- Trial name
- REST (NCT01475474)
- Testing
- Renew Insert
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Renew Medical
Parkinson's Disease
Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
This study is to determine if Viagra is effective in reducing dyskinesias in patients with Parkinson's Disease.
- Trial name
- NCT02162979
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Loma Linda University
Parkinson Disease
Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms
Parkinson disease (PD) is characterized by substantial disability and reduced quality of life, both of which can be attributed in large part to difficulties with walking.
- Trial name
- NCT01768832
- Testing
- Treadmill, Tango, Stretching
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Washington University School of Medicine
Parkinson Disease
a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
This is an open-label, multicenter, non-interventional, prospective observational study. we collect the safety information of pramipexole over 12w treatment.
- Trial name
- NCT01361009
- Testing
- pramipexole
- Where
- 103 sites in China
- Volunteers
- 2,017 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease, Helicobacter Infections
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Trial name
- NCT00664209
- Testing
- clartihromycin, amoxicillin, and omeprazole
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Multiple System Atrophy
Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
MSA is a rapidly progressive disorder with an average survival time of about 7 years after the first clinical manifestation. No potent symptomatic treatment is currently available.
- Trial name
- PROMESA (NCT02008721)
- Testing
- EGCG as putative neuroprotective agent
- Where
- 12 sites in Germany
- Volunteers
- 92 people
- Sponsor
- Dr. Johannes Levin
Parkinson's Disease
Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications.
- Trial name
- NCT00282152
- Testing
- B-STN DBS, Optimal drug therapy
- Volunteers
- 37 people
- Sponsor
- Vanderbilt University Medical Center
Huntington Disease
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F.
- Trial name
- NCT03842969
- Testing
- RO7234292 (RG6042)
- Where
- 38 sites in United States, Austria and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
This is a phase III, multicenter, randomized, double-blind, parallel group, placebo-controlled study to compare the efficacy of 6-months therapy of ropinirole Prolonged Release (PR) with that of placebo as adjunctive therapy to…
- Trial name
- NCT01154166
- Testing
- ReQuip PR
- Where
- 18 sites in China
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Huntington Disease, Chorea
Citalopram to Enhance Cognition in HD
This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1.
- Conditions
- Huntington Disease, Chorea, Executive Dysfunction
- Trial name
- CIT-HD (NCT00271596)
- Testing
- 20mg daily citalopram
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Wilson Disease
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6 (CYP2B6) substrate, in healthy male and female…
- Trial name
- NCT04526210
- Testing
- ALXN1840, Bupropion Hydrochloride
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Dystonia, Primary
An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
This is a single-center, open-label study of AUSTEDO in study subjects with dystonia. The study will provide preliminary experience of the safety, tolerability, and clinical activity of AUSTEDO in study subjects with dystonia.
- Trial name
- AUDYT (NCT04173260)
- Testing
- Deutetrabenazine 6 MG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pennsylvania
Dementia, Dementia With Lewy Bodies
Monitoring Anti-Dementia Drugs by Serum Levels
The main objective of the MONANTI study is twofold: Firstly, to determine the serum concentration (SC) the anti-dementia drugs donepezil and memantine in a broadly defined clinical population of patients suffering from dementia…
- Conditions
- Dementia, Dementia With Lewy Bodies, Dementia in Parkinsons Disease, Dementia Alzheimers
- Trial name
- MONANTI (NCT04117178)
- Testing
- Donepezil, Memantine, Measurement of serum level of anti-dementia drug
- Where
- Denmark
- Volunteers
- 132 people
- Sponsor
- Zealand University Hospital
Parkinson Disease
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
This is an open-label, prospective post marketing surveillance study to be performed in Sweden. Only data of patients idiopathic PD should be documented, in whom the treating physician plans to initiate a pharmacotherapy with PPX…
- Trial name
- NCT01097421
- Testing
- Pramipexole Extended Release
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Telemedicine Intervention to Improve Cognitive Function
This project is investigating whether a home-based exercise program will reduce cognitive decline in patients with Parkinson's disease.
- Trial name
- NCT02248649
- Testing
- Structured physical activity, Health education
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- VA Office of Research and Development
Idiopathic Parkinson Disease
Effect of Safinamide on Parkinson's Disease Related Chronic Pain
Primary objective: To evaluate the potential efficacy of safinamide 100 mg once daily (OD), compared with placebo, as add-on therapy for PD-related chronic pain Secondary objectives: Percentage of pain responders Clinical Global…
- Trial name
- NCT03841604
- Testing
- Safinamide Methanesulfonate
- Where
- 45 sites in Austria, France and 3 more
- Volunteers
- 94 people
- Sponsor
- Zambon SpA